CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. Endocr Pract. 2016 Sep;22(9):1111-8. \[[PubMed: 27643923](https://pubmed.ncbi.nlm.nih.gov/27643923)\] 8. Singer FR. Clinical efficacy of salmon calcitonin in Paget's disease of bone. Calcif Tissue Int. 1991;49 Suppl 2:S7-8. \[[PubMed: 1933617](https://pubmed.ncbi.nlm.nih.gov/1933617)\] 9. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008 Sep;83(9):1032-45. \[[PMC free article: PMC2667901](/pmc/articles/PMC2667901/)\] \[[PubMed: 18775204](https://pubmed.ncbi.nlm.nih.gov/18775204)\] 10. Wootton R, Reeve J, Spellacy E, Tellez-Yudilevich M. Skeletal blood flow in Paget's disease of bone and its response to calcitonin therapy. Clin Sci Mol Med. 1978 Jan;54(1):69-74. \[[PubMed: 620495](https://pubmed.ncbi.nlm.nih.gov/620495)\] 11. Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum. 1980 Oct;23(10):1148-54. \[[PubMed: 7000081](https://pubmed.ncbi.nlm.nih.gov/7000081)\] 12. Reginster JY, Lecart MP. Efficacy and safety of drugs for Paget's disease of bone. Bone. 1995 Nov;17(5 Suppl):485S-488S. \[[PubMed: 8573423](https://pubmed.ncbi.nlm.nih.gov/8573423)\] 13. Luboshitzky R, Bar-Shalom R. [Calcitonin nasal spray for Paget's disease of the bone]. Harefuah. 1995 Mar 15;128(6):358-62, 399. \[[PubMed: 7750816](https://pubmed.ncbi.nlm.nih.gov/7750816)\] 14. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med. 1981 Autumn;50(200):473-81. \[[PubMed: 7342172](https://pubmed.ncbi.nlm.nih.gov/7342172)\] 15. Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int. 1990;46 Suppl:S26-30. \[[PubMed: 2137363](https://pubmed.ncbi.nlm.nih.gov/2137363)\] 16. Bilezikian JP. Clinical review 51: Management of hypercalcemia. J Clin Endocrinol Metab. 1993 Dec;77(6):1445-9. \[[PubMed: 8263125](https://pubmed.ncbi.nlm.nih.gov/8263125)\] 17. Nilsson O, Almqvist S, Karlberg BE. Salmon calcitonin in the acute treatment of moderate and severe hypercalcemia in man. Acta Med Scand. 1978;204(4):249-52. \[[PubMed: 358762](https://pubmed.ncbi.nlm.nih.gov/358762)\] 18. Stevenson JC. Current management of malignant hypercalcaemia. Drugs. 1988 Aug;36(2):229-38. \[[PubMed: 3053127](https://pubmed.ncbi.nlm.nih.gov/3053127)\] 19. Masi L, Brandi ML. Calcitonin and calcitonin receptors. Clin Cases Miner Bone Metab. 2007 May;4(2):117-22. \[[PMC free article: PMC2781237](/pmc/articles/PMC2781237/)\] \[[PubMed: 22461211](https://pubmed.ncbi.nlm.nih.gov/22461211)\] 20. Felsenfeld AJ, Levine BS. Calcitonin, the forgotten hormone: does it deserve to be forgotten? Clin Kidney J. 2015 Apr;8(2):180-7. \[[PMC free article: PMC4370311](/pmc/articles/PMC4370311/)\] \[[PubMed: 25815174](https://pubmed.ncbi.nlm.nih.gov/25815174)\] 21. Niall HD, Keutmann HT, Copp DH, Potts JT. Amino acid sequence of salmon ultimobranchial calcitonin. Proc Natl Acad Sci U S A. 1969 Oct;64(2):771-8. \[[PMC free article: PMC223410](/pmc/articles/PMC223410/)\] \[[PubMed: 5261048](https://pubmed.ncbi.nlm.nih.gov/5261048)\] 22. Andreotti G, MÃ©ndez BL, Amodeo P, Morelli MA, Nakamuta H, Motta A. Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix. J Biol Chem. 2006 Aug 25;281(34):24193-203. \[[PubMed: 16766525](https://pubmed.ncbi.nlm.nih.gov/16766525)\] 23. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin